M

Targeted Therapies in the Treatment of MCL

By Michael Buege
87 views
May 24, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
10:27
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Rates of CRS and ICANS From CIBMTR Data o…

Feat. J. DiPersio
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
05:38
GRACE

Epcoritamab in NHL - Incidence and Management of CRS

Feat. T. Phillips
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
31:12
UChicago Medicine

Practice-Changing Abstracts in NHL and HL From ASH 2023

Feat. S. Smith
37:44
University of Colorado Division of Hematology

Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas

Feat. M. Kamdar
04:34
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Highlights and Key Takeaways in MCL"

Feat. P. Jain
26:58
Total Health

Update on Cellular Therapy in Lymphoma

Feat. B. Randolph
16:05
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is High Risk MCL and How Should We Treat It

Feat. A. Kumar
06:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MCL - Highlights & Key Takea…

Feat. V. Yazbeck
07:22
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Hypertension in Pts With CLL and Other Heme…

Feat. A. Ferrajoli
05:24
Chan Cheah

Efficacy of Pirtobrutinib in Covalent BTKi Pre-Treated R/R MCL: Addi…

05:28
GRACE

3L Treatment for Mantle Cell Lymphoma

Feat. T. Phillips
33:11
Total Health

Bispecific Antibodies and CAR T-Cells for NHL: Challenges and Opport…

Feat. K. Komanduri